Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 5.04 | 4.70984020185 | 107.01 | 112.38 | 106.0982 | 7725390 | 109.23153951 | CS |
| 4 | -2.835 | -2.46768507638 | 114.885 | 119.96 | 104.7 | 10719858 | 111.85130977 | CS |
| 12 | 21.15 | 23.2673267327 | 90.9 | 119.96 | 88.57 | 8911871 | 104.84993537 | CS |
| 26 | 28.9 | 34.7564642213 | 83.15 | 119.96 | 82.82 | 7486285 | 98.2179158 | CS |
| 52 | 38.83 | 53.0319584813 | 73.22 | 119.96 | 62.07 | 7287903 | 85.20649393 | CS |
| 156 | 52.08 | 86.8434217109 | 59.97 | 119.96 | 57.165 | 6926045 | 78.13923409 | CS |
| 260 | 36.1 | 47.5312705727 | 75.95 | 119.96 | 56.56 | 7901083 | 73.54024055 | CS |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
